Literature DB >> 17991582

Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.

Satoshi Anai1, Kathleen Shiverick, Theresa Medrano, Kogenta Nakamura, Steve Goodison, Bob D Brown, Charles J Rosser.   

Abstract

OBJECTIVES: Our group previously demonstrated that expression of the oncogene, Bcl-2, was associated with radiation resistance. The aim of the present study was to determine whether Bcl-2 expression in radiation-resistant tumors was associated with expression of carbonic anhydrase IX (CAIX), vascular endothelial growth factor (VEGF), and pAkt and whether downregulation of Bcl-2 could modulate the expression of CAIX, VEGF, and pAkt.
METHODS: Two prostate cancer cell lines, PC-3-Bcl-2 and PC-3-Neo, were injected into the subcutaneous flanks of 192 athymic male nude mice; 96 received PC-3 Bcl-2 and 96 PC-3-Neo. The mice were then treated with antisense Bcl-2 oligodeoxynucleotide (ASODN), reverse control ODN, or vehicle only (mock treatment) with or without irradiation (4 Gy). The tumors were monitored for growth (ie, volume) over time, resected at various points, and processed and sectioned for protein analyses.
RESULTS: Bcl-2 ASODN treatment was associated with downregulation of Bcl-2, VEGF, pAkt, and CAIX. PC-3-Bcl-2 and PC-3-Neo prostate tumor xenografts in mice treated with the combination of Bcl-2 ASODN and irradiation were significantly (ie, one third) smaller than those in mice treated with reverse control ODN alone, Bcl-2 ASODN alone, irradiation alone, or reverse control ODN plus irradiation (P = 0.0001). An increased tumor response to the combined therapy was associated with decreased expression of Bcl-2, VEGF, and pAkt proteins.
CONCLUSIONS: These findings have demonstrated an intimate relationship among CAIX, VEGF, pAkt, and Bcl-2 in prostate tumors. Thus, CAIX might prove effective as a potential marker of tumor radiation resistance. Downregulation of CAIX might lead to radiation sensitization. Consequently, the combination of CAIX reduction and radiotherapy warrants further consideration as a new strategy for therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991582     DOI: 10.1016/j.urology.2007.06.1118

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.

Authors:  Rita Garcia-Parra; David Wood; Rajal B Shah; Javed Siddiqui; Hero Hussain; Hyunjin Park; Timothy Desmond; Charles Meyer; Morand Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-16       Impact factor: 9.236

2.  Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.

Authors:  D Trisciuoglio; C Gabellini; M Desideri; Y Ragazzoni; T De Luca; E Ziparo; D Del Bufalo
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

3.  The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Authors:  Chloe Stengel; Simon P Newman; Mathew P Leese; Mark P Thomas; Barry V L Potter; Michael J Reed; Atul Purohit; Paul A Foster
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

4.  Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.

Authors:  Caroli Genis; Katherine H Sippel; Nicolette Case; Wengang Cao; Balendu Sankara Avvaru; Lawrence J Tartaglia; Lakshmanan Govindasamy; Chingkuang Tu; Mavis Agbandje-McKenna; David N Silverman; Charles J Rosser; Robert McKenna
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

5.  Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

Authors:  Lydia Livas; Sumati Hasani; Natasha Kyprianou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway.

Authors:  Zhiwei Wang; Asfar Sohail Azmi; Aamir Ahmad; Sanjeev Banerjee; Shaomeng Wang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 7.  Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents.

Authors:  Hidetomo Kikuchi; Bo Yuan; Xiaomei Hu; Mari Okazaki
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

8.  Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.

Authors:  Ashiq Masood; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancers (Basel)       Date:  2011-06-01       Impact factor: 6.639

9.  BAIAP2L2 facilitates the malignancy of prostate cancer (PCa) via VEGF and apoptosis signaling pathways.

Authors:  Yuanzi Song; Guishan Zhuang; Jiazhen Li; Mingqing Zhang
Journal:  Genes Genomics       Date:  2021-03-01       Impact factor: 2.164

10.  ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.

Authors:  Ji-Yu Li; Yu-Yang Li; Wei Jin; Qing Yang; Zhi-Ming Shao; Xing-Song Tian
Journal:  J Exp Clin Cancer Res       Date:  2012-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.